Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKD3 | O94806 | 1/20 | 0.33 |
| ▸ | PRKCG | P05129 | 1/20 | 0.33 |
| ▸ | PRKCB | P05771 | 1/20 | 0.33 |
| ▸ | PRKCA | P17252 | 1/20 | 0.33 |
| ▸ | PRKCH | P24723 | 1/20 | 0.33 |
| ▸ | PRKCE | Q02156 | 1/20 | 0.33 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.33 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.33 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 2/20 | 0.32 |
| ▸ | PARP1 | P09874 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9790400 | 0.71 | MAPT (0.39) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL5138055 | 0.70 | PARP1 (0.43) | PARP1 | |
| SCHEMBL6626202 | 0.65 | GAA (0.30) | — | |
| SCHEMBL549329 | 0.65 | CREBBP (0.46) | — | |
| SCHEMBL30124040 | 0.64 | NOS2 (0.40) | PARP1 | |
| SCHEMBL12580789 | 0.62 | NPC1 (0.42) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL261440 | 0.60 | MAPT (0.45) | PRKD3PRKCGPRKCBPRKCAPRKCH | |
| SCHEMBL12828352 | 0.59 | PARP1 (0.36) | PARP1 | |
| SCHEMBL3684946 | 0.59 | — | — | |
| SCHEMBL261443 | 0.58 | BRPF1 (0.47) | PRKD3PRKCGPRKCBPRKCAPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | claimed |
| EP-4028009-A1 | TREATMENT OF HR DEFICIENT CANCER | The Francis Crick Institute Limited (GB) | 2022-07-20 | — | — | EP | disclosed |
| US-20210322475-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE UAB RESEARCH FOUNDATION | 2021-10-21 | — | — | US | disclosed |
| EP-3877514-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | In8bio, Inc. (US) | 2021-09-15 | — | — | EP | disclosed |
| US-20210244706-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-08-12 | — | — | US | disclosed |
| WO-2021048235-A1 | TREATMENT OF HR DEFICIENT CANCER | THE FRANCIS CRICK INSTITUTE LIMITED (GB) | 2021-03-18 | — | — | WO | disclosed |
| US-20210046072-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | KING'S COLLEGE LONDON (GB) | 2021-02-18 | — | — | US | disclosed |
| US-10799501-B2 | Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L | KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST (GB) | 2020-10-13 | — | — | US | disclosed |
| US-20190076427-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST (GB) | 2019-03-14 | — | — | US | disclosed |
| US-20190022176-A1 | USE OF MK2 INHIBITOR PEPTIDE-CONTAINING COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER WITH SAME | MOERAE MATRIX, INC. | 2019-01-24 | — | — | US | disclosed |
| WO-2012151701-A1 | METHODS FOR THE TREATMENT AND DIAGNOSTIC OF PULMONARY ARTERIAL HYPERTENSION | UNIVERSITÉ LAVAL / VICE-RECTORAT À LA RECHERCHE ET À LA CRÉATION (CA) | 2012-11-15 | — | — | WO | disclosed |
| US-20120135983-A1 | DNA Damage Repair Inhibitors for the Treatment of Cancer | The Institute of Cancer Reseach | 2012-05-31 | — | — | US | disclosed |
| US-8143241-B2 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-03-27 | — | — | US | disclosed |
| EP-1684736-B1 | DNA DAMAGE REPAIR INHIBITORS FOR TREATMENT OF CANCER | KUDOS PHARM LTD (GB) | 2011-08-24 | — | — | EP | disclosed |
| WO-2011058367-A2 | DIAGNOSTIC TEST FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITOR | ASTRAZENECA AB (SE) | 2011-05-19 | — | — | WO | disclosed |
| EP-2305221-A1 | Dna damage repair inhibitors for treatment of cancer | Kudos Pharmaceuticals Limited (GB) | 2011-04-06 | — | — | EP | disclosed |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA R&D (SE) | 2010-09-30 | — | — | US | disclosed |
| EP-2167086-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | AstraZeneca AB (SE) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008146035-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | WO | disclosed |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | KUDOS PHARMACEUTICALS LIMITED (GB) | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135983-A1 | DNA Damage Repair Inhibitors for the Treatment of Cancer | MRE11, ERCC4, PARP2 | PRKD3 671/4885PRKCG 1405/4885PRKCB 1111/4885 |
| US-20210046072-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | PARP3, PARP11, GSK3A | PRKD3 169/4885PRKCG 961/4885PRKCB 538/4885 |
| US-20190022176-A1 | USE OF MK2 INHIBITOR PEPTIDE-CONTAINING COMPOSITIONS FOR TREATING NON-SMALL CELL LUNG CANCER WITH SAME | MKNK2, KSR2, MKNK1 | PRKD3 700/4885PRKCG 259/4885PRKCB 346/4885 |
| US-10799501-B2 | Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L | PARP3, PARP11, GSK3A | PRKD3 169/4885PRKCG 961/4885PRKCB 538/4885 |
| US-20060142231-A1 | DNA damage repair inhibitors for treatment of cancer | MRE11, PARP2, ERCC4 | PRKD3 636/4885PRKCG 1328/4885PRKCB 982/4885 |
| US-20190076427-A1 | COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L | PARP3, PARP11, GSK3A | PRKD3 169/4885PRKCG 961/4885PRKCB 538/4885 |
| US-20100249112-A1 | COMBINATION OF CHK AND PARP INHIBITORS FOR THE TREATMENT OF CANCERS | CHEK1, CHEK2, PARP1 | PRKD3 620/4885PRKCG 610/4885PRKCB 502/4885 |
| US-20210244706-A1 | DNA Damage Repair Inhibitors for Treatment of Cancer | PARP2, MRE11, PARP1 | PRKD3 572/4885PRKCG 1302/4885PRKCB 1039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.